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of Diseases (ICD)-9 diagnosis codes 381 or 382. Incremental total expenditures 
associated with OM were estimated using a regression model adjusting for age, 
gender, race, ethnicity, education, geographic region, insurance status and 
number of medications used (proxy for comorbidity). Given the skewed 
distribution of expenditure variables, multiple model specifications including 
ordinary least squares regression, generalized linear model (GLM) with Poisson, 
gamma and negative binomial variance functions were evaluated. RESULTS: The 
prevalence of OM among children in the US was estimated at 11.32%, i.e., 8.47 
million persons (95% CI: 10.30% to 12.33%). A majority of children with OM were 
male (51.7%), white (84.2%), and insured (97.3%) with mean age of 4.7±0.20 years 
and education of 0.9±0.11 years. In unadjusted analysis among patients with OM, 
physician office visits comprised the largest proportion of total expenditures at 
$769.06 (SE: 54.99), followed by prescription medications at $606.56 (SE: $41.72), 
and inpatient visits at $500.73 (SE: $148.42). After controlling for covariates, 
children with OM had 48% higher total expenditures than those without OM 
(Estimate: 1.48; p=0.001). The annual adjusted mean incremental total 
expenditure associated with OM was $543.10 (SE: $192.0; p=0.005) per person. 
CONCLUSIONS: Given the prevalence of OM in children and its associated 
incremental expenditures, the annual direct medical expenditure for treating OM 
in children is estimated at approximately $4.6 billion in 2012 US dollars.  
 
PHS19  
DIRECT MEDICAL COSTS ASSOCIATED WITH EXACERBATIONS RELATED TO 
NON-CYSTIC FIBROSIS BRONCHIECTASIS  
Joish VN1, Spilsbury-Cantalupo M2, Kamalakar R3, Operschall E4, Luong B5 
1Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ, USA, 2Bayer HealthCare Pharmaceuticals, 
Inc, Wayne, NJ, USA, 3Bayer Pharmaceuticals, Wayne, NJ, USA, 4Bayer Schering Pharma, AG, 
Berlin, Berlin, Germany, 5Bayer Pharma AG, Berlin, Berlin, Germany  
OBJECTIVES: To estimate direct medical costs in non-cystic fibrosis 
bronchiectasis (NCB) patients with exacerbations. METHODS: An observational, 
retrospective cohort study was conducted using data from MarketScan claims 
database. Bronchiectasis patients were identified as those with a medical claim 
with ICD-9 codes of 494.0 or 494.1 anytime between July 1, 2009 to June 30, 2010. 
The first bronchiectasis-related claim during this period was defined as the 
index event. All patients had to have no other bronchiectasis related medical 
claim 12-months before the index event and no cystic fibrosis related medical 
claim (ICD-9 code:277.0) 12-months before and after index event. NCB patients 
were divided into two cohorts. Each NCB patient with exacerbation (NCB-E) was 
matched to three NCB patients without exacerbations (NCB-W) on geographic 
region, health plan and gender. Medical resource use and expenditures were 
estimated for 12-months before and after index event and compared between 
the two cohorts using non-parametric univariate statistical tests. RESULTS: 897 
NCB-E patients were matched to 2,691 NCB-W patients. NCB-E patients were 
older (67 vs. 64, p<0.01), had greater overall comorbidity as estimated by the 
Charlson’s comorbidity score (1.83 vs. 1.66, p=0.01), and respiratory/chest-related 
symptoms (73% vs. 66%, p<0.001) at baseline compared to NCB-W patients. Total 
average costs per patient post index-event were significantly greater among 
NCB-E versus NCB-W patients ($35,718 vs. $26,868). After adjusting for baseline 
health care expenditures, the overall annual average incremental burden due to 
exacerbations were estimated to be $7,643. Of this, inpatient hospital costs 
accounted for $5,772 or 75% of this burden. Bronchiectasis-related total costs 
were also significantly (p<0.001) higher in the follow-up period among NCB-E 
patients compared to NCB-W patients ($4,609 vs. $1,210), even after adjusting for 
baseline consumption. CONCLUSIONS: NCB patients with exacerbations have 
greater medical expenditures than those without. Effective management of 
exacerbations may be the key in controlling economic burden in this patient 
population.  
 
PHS20  
DIRECT MEDICAL COSTS OF DIABETIC COMPLICATIONS IN THE UNITED 
STATES  
Alvarez P1, Ward A1, Chow W2, Vo L2, Martin S2 
1United BioSource Corporation, Lexington, MA, USA, 2Janssen Scientific Affairs, LLC, Raritan, NJ, 
USA  
OBJECTIVES: To estimate the direct medical costs associated with managing 
complications of type 2 diabetes in the United States. METHODS: A combination 
of direct data analysis and microcosting was used to estimate costs for an event 
leading to either a hospital admission or outpatient care, and the post-acute care 
associated with managing macrovascular, microvascular, and other 
complications. Data were obtained from many sources, including inpatient and 
emergency department care databases, national physician and laboratory fee 
schedules, government reports, and published literature. For each complication, 
the event year costs derived refer to those associated with the acute episode and, 
when appropriate, include subsequent ongoing care provided within the first 
year following the acute episode. Annual costs after the first year for the 
continued management of complications were also estimated. All costs are 
reported in 2012 USD. RESULTS: Annual costs accrued per patient in the year of 
the event were estimated for the following macrovascular complications: 
myocardial infarction $56,445, ischemic stroke $42,119, congestive heart failure 
$23,758, ischemic heart disease $21,406, and transient ischemic attack $7,388. 
Event year costs per patient for microvascular complications were: chronic 
kidney disease $71,714, lower extremity amputations $9,041, blindness  
$2,862, and diabetic foot ulcers $2,147. Cost estimates of a medically managed 
hypoglycemic episode were: $176, $1,311, and $16,478 for a mild, moderate, or 
severe (i.e., requiring hospitalization) episode. CONCLUSIONS: This study 
provides updated and additional estimates of the cost of diabetic complications 
in 2012 USD, following the methodology used to generate prior cost estimates in 
2000 USD referenced in many diabetes economic models (O’Brien et al.  
Clin Ther 2003;25(3):1017-1038). Managing complications results in substantial 
costs to the health care system, as macrovascular complications yield high 
inpatient care costs in the event year, and long-term management of 
complications such as chronic kidney disease lead to substantial ongoing annual 
costs.  
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OBJECTIVES: São Paulo is a Brazilian state with the largest number of cancer 
reference hospitals and hosts 21% of country population. This study aims to 
describe hospitalization patterns and costs for renal cell carcinoma (RCC) in 
public hospitals in São Paulo state, Brazil. METHODS: A retrospective analysis of 
São Paulo public hospital admissions for RCC was developed according to ICD-10 
classification (C64) as reported in Brazilian Hospital Information System 
(SIH/DATASUS) database from January 2007 to December 2011. Admissions were 
categorized into surgical (containing any surgical procedures codes at 
hospitalization data eg.: tumor excision, biopsy, etc.) or clinical (all non-surgical 
eg.: chemotherapy, infection treatment, anemia, etc.). Costs represent federal 
reimbursement values for hospitalizations (includes medical procedures, exams, 
medications and taxes), presented in 2012 Brazilian Real (BRL). Average 2012 
exchange rate was 1,9544BRL/USD. RESULTS: In the period, 4,138 hospital 
admissions were identified (951, 1,126, 1,207, and 854 for 2007, 2008, 2009, and 
2011, respectively), and total cost was 5,472,534BRL, which represents 0.78% of all 
cancer in-hospital treatment in the state. Mean cost per patient was 1,326BRL, 
675BRL, and 1,854BRL for all hospitalizations, clinical and surgical procedures, 
respectively. Surgical procedures were responsible for 55.07% of cases, and 
77.29% of total costs, with partial or total nephrectomy representing the main 
cause (48.9%). Mean length of stay was 6.99 days. In-hospital mortality rate was 
9.98% for all cause (17.7% and 3.69% for clinical and surgical procedures, 
respectively). When compared to the national cases, São Paulo represents 29.74% 
of them, while representing 33.18% of total national hospitalization costs related 
to RCC. CONCLUSIONS: RCC hospitalizations costs in São Paulo are responsible 
for less than 1% of all cancer in-hospital treatments in the state, which may 
suggest under-diagnosing when compared to international incidence rates. São 
Paulo is an important RCC treatment center in Brazil, capturing about one third 
of country resources.  
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OBJECTIVES: To determine the cost and health care resource utilization 
associated with asthma management in Canada. METHODS: A systematic 
literature search of PUBMED, EMBASE and EMCare electronic databases using 
relevant search strategy was conducted from 2000 until 2011 to identify articles, 
published in English, that reported the data on the clinical and economic burden 
of asthma in Canada. Two investigators independently screened citations, 
reviewed studies, assessed study quality and abstracted data. Heterogeneity in 
study design, data sources and asthma definition precluded meta-analysis of 
study outcomes. All costs were reported in Canadian dollars and inflated to 2011. 
RESULTS: Of the 570 citations identified, 67 full-text articles were reviewed, of 
which 33 studies met inclusion criteria. Both children and adults with asthma 
averaged less than one emergency department (ED) visit per patient per year. In 
children, frequency of visits was largely influenced by the presence of prior 
asthma exacerbations. In adults, increased ED visits were associated with 
inappropriate use of asthma medication. ED visit rates were significantly higher 
in women than in men and, increased with age. Hospitalization rates in children 
decreased with age and patients with persistent asthma were more than one and 
a half times admitted more often than those with non-symptomatic asthma. 
Average hospitalization costs per acute asthma episode ranged from $458 to $923 
and the average costs for ED visit per acute asthma episode ranged from $219.08 
to $276.76, excluding medication cost. The average annual cost of asthma 
medication was $230.58 per patient. Annual productivity loss days in adult 
asthma patients varied from 12 in employed persons to 20 in students and 49 in 
disability pensioners. CONCLUSIONS: The available evidence shows that the 
asthma-related costs, both direct and indirect remain substantial. The overall 
burden varies based on whether studies reported costs from the perspective of 
an individual asthmatic or from the population level.  
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OBJECTIVES: To describe treatment patterns, direct costs and comorbidities in a 
population of patients with melanoma. METHODS: Starting from ARNO 
Observatory, an Italian population-based patient-centric system through record 
linkage of 11 million inhabitants, we identified a cohort of patients with 
melanoma (ICD-9 code: 172 and/or V10.82) during 2009. Discharge records, 
reimbursed prescription patterns, lab tests and diagnostic examinations were 
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analyzed for 365 days after and before the accrual period. RESULTS: On a total of 
2,962,498 subjects observed, 594 patients were hospitalized for melanoma (53.4% 
males) during 2009 (prevalence rate: 20.0 per 100,000). Among them, 43% had at 
least one chronic comorbidity, hypertension is the most common (14.6%) 
followed by combination of dyslipidemia and hypertension (3.0%). Therapy for 
melanoma is made both in and outside the hospital. Interferon alfa-2b was the 
most prescribed treatment outside the hospital with an average cost of €110, 
followed by Temozolomide (€40.7) and Erythropoietin (€39.6). During one-year of 
follow-up, 13% of patients was hospitalized for chemotherapy with an average 
cost of €7398. This amount covers also drug treatment cost during 
hospitalization. The average yearly cost/patient for population with melanoma 
was €4777 (hospitalizations: 70.8%, drugs: 14.4%, diagnostic examinations: 
14.8%), with an higher cost for the subgroup of patient already in treatment the 
previous year before the accrual period (€6156 vs €4361). If we consider the 
subgroup of patient with metastatic melanoma (N=176), the overall cost rises at 
€15,984, most of it (60%) due to drug costs for specific therapy of melanoma and 
chemotherapy. Surprisingly methotrexate and cyclophosphamide appear in the 
top five list of prescribed drugs. CONCLUSIONS: This study shows high cost of 
patients with melanoma and how real world practice therapy, especially for 
metastatic melanoma, seems to be far from the guidelines recommendation. 
This suggests to create a regional network to correctly redirect therapeutic 
choices.  
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OBJECTIVES: Diabetes mellitus (DM) is recognised as a major health problem. Its 
chronic nature and complications make it a costly disease. The aim of this study 
is two-fold: (1) to describe the methods used in the identified cost-of-illness (COI) 
studies of DM and (2) to summarise their study findings regarding the economic 
impact of DM. METHODS: This is a systematic review of MEDLINE and Scopus 
journal articles reporting the cost of type-1 and/or type-2 DM that were 
published in English from 2007 to 2011. Costs reported in the included studies 
were converted to US dollars for comparison purposes. RESULTS: The systematic 
search yielded 30 articles that met the predetermined criteria. The studies varied 
considerably in their study design, perspective and included cost categories. 
Estimates for the total annual costs of DM ranged from US$141.6 million to 
US$174 billion; direct costs ranged from US$150 to US$14,060 per patient per year 
(pppy) whereas indirect costs ranged from US$39.6 to US$7,164 pppy. Inpatient 
cost was the major contributor to direct cost in half of the studies that included 
inpatient costs, physician services and medications. In addition, patients with 
DM consumed significantly more health care resources and incurred higher 
health care costs than patients without DM. CONCLUSIONS: There is a 
considerable economic burden associated with DM, not only on the health care 
system, but also on the individual and society as a whole. Future research should 
focus on improving methods of estimating costs, enhancing the interpretation of 
study findings and facilitating comparisons between studies.  
 
PHS25  
DIRECT HEALTH CARE COSTS IN PATIENTS WITH PULMONARY ARTERIAL 
HYPERTENSION IN THE NATIONAL INSTITUTE OF CARDIOLOGY "IGNACIO 
CHÁVEZ" (NIC), MEXICO CITY  
Rely K1, Pulido Zamudio T2, Escamilla C3, Ramírez-Neria P2, Vazquez A4, Cañedo A5 
1CEAHealthTech, Mexico City, D.F., Mexico, 2Instituto Nacional de Cardiología - Ignacio Chávez, 
Mexico City, Mexico, 3INSP, Mexico City, Mexico, 4Actelion Pharmaceuticals Mexico, Mexico City, 
Mexico, 5Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico  
OBJECTIVES: To evaluate the cost of Pulmonary Arterial Hypertension (PAH) to 
health services in Mexico based on epidemiological trends, to project this 
estimate to 2012. METHODS: Retrospective medical chart review using data from 
the NIC. Clinical and resource utilization data for all patients admitted to the NIC 
with PAH between January 1, 2009 and 2011 were collected and the mean 
treatment costs per person were calculated by assigning appropriate unit cost 
data to all resource use. A prevalence based approach was used to estimate the 
economic burden of PAH. Contemporary data were obtained from 
epidemiological studies, government datasets, and other sources to estimate 
prevalence. National costs (US dollar 2012) of treatment for PAH were estimated 
by extrapolation of mean cost estimate per person to national incidence data for 
PAH. Because of uncertainties surrounding some of our estimates such as 
prevalence, one way sensitivity analyses were undertaken. RESULTS: A total of 
113 PAH patients were identified and their demographic and clinical 
characteristics, patterns of care were examined. The mean age was 38 years, and 
83% were female. The average per patient annual cost was $ 10,869 without 
specific treatment (min $ 137; max $155,928). The annual cost for the treatment 
of a single PAH patient per year with specific therapy (Bosentan) was calculated 
in $31.433. Aggregate national health care expenditures for treatment of PAH 
were USD 46.6 million In multivariate analysis, length of hospital stay, stay in 
ICU, were all significant independent predictors of treatment CONCLUSIONS: 
Treatment costs of PAH in Mexico are substantial and primarily driven by the 
intensity of hospital treatment. With the expected increase in the incidence of 
PAH in Mexico over the coming decades, these results emphasize the need for 
effective preventive and acute medical care.  
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OBJECTIVES: The current study aimed to examine direct medical cost and 
humanistic outcome of diastolic heart failure (DHF) management in Hong Kong. 
Whether the presence of comorbidities, including hypertension, diabetes and 
renal impairment, affect the cost and humanistic outcome was also evaluated. 
METHODS: Retrospective, non-randomized study design was adopted. Subjects 
were recruited from the Heart Failure Registry of the Prince of Wales Hospital in 
Hong Kong between 2006 and 2008 and completion of the Minnesota Living with 
Heart Failure Questionnaire (MLHFQ) at 3 designated time pints to be eligible. 
Patients with significant valvular disorder were excluded. One year medical 
records since admission were reviewed. Heart failure related admissions, clinic 
visits, cardiovascular drugs, laboratory and diagnostic tests were recorded. The 
costs and MLHFQ scores in patients with or without hypertension, diabetes, and 
renal impairment were compared. Non-parametric Wilcoxon Signed Rank and 
Mann-Whitney tests were used. A p-value < 0.05 was considered statistically 
significant. RESULTS: A total of 73 DHF patients were included. The mean 1-year 
direct medical cost was USD 20,098 (1 USD = 7.75 HKD), with in-patient care cost 
contributing to the largest proportion (72.2%) of the total cost. Patients with 
diabetes or renal impairment were associated with a higher cost of DHF 
management. Significant difference was found in the renal impairment group 
(median cost: USD 24,763 versus USD 12,789 in no impairment group, p=0.023). 
The mean MLHFQ scores of the subjects improved significantly from baseline 
30.81±13.89 to 12 months 15.84 ±11.32 (p<0.0005). CONCLUSIONS: The cost of 
management of DHF was shown to be enormous and further increased in the 
presence of comorbidities. With the aging population in Hong Kong, the 
incidence of DHF is expected to increase progressively. Further studies are 
demanded to guide more optimal medical resource allocation for DHF 
management.  
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OBJECTIVES: Prostate cancer is the second leading cancer diagnosed among 
men. In Spain the incidence of prostate cancer was 100.4 cases per 100,000 
males. Advanced prostate cancer is cancer that has spread outside of the 
prostate capsule and may involve other parts of the body, most commonly to the 
lymph nodes and bones . The aim of this study was to estimate the lifetime costs 
of a cohort of advanced prostate cancer patients diagnosed in Spain in 2012. 
METHODS: An economic model was developed in EXCEL incorporating Spanish 
incidence, mortality and cost data supplemented with data from the 
international literature. Progression from Stage III to Stage IV was permitted. 
Costs were discounted. Lifetime costs were presented on an individual basis and 
for the entire cohort of newly diagnosed Stage III and Stage IV prostate cancer 
patients. RESULTS: Lifetime costs for advanced prostate cancer were 
approximately 23,032 € per patient. Using the projected incident cases for 2012, 
the total cost for the incident cohort of patients in 2012 would amount to 172 
million euros. These results were more sensitive to changes in the ongoing costs 
(post initial 12 months) of Stage III prostate cancer, the rate of progression from 
Stage III to Stage IV and the discount rate applied to costs. CONCLUSIONS: This 
study provides an estimate of the lifetime costs of advanced prostate cancer in 
Spain and a framework for further research. Until improved long-term 
prospective or observational data do become available the current results 
indicate that the burden of advanced prostate cancer is substantial and will 
increase due to an increasing number of new cases and reductions in mortality. 
Any treatments that could potentially reduce the economic burden of the disease 
should be of interest to health care decision makers given the context of limited 
resources in Europe.  
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OBJECTIVES: To evaluate the health care cost of diabetes with co-morbidities by 
using cost of illness analysis. METHODS: A prospective observational study was 
conducted for a period of six months at Rohini super specialty hospital, AP, 
India. The patients were identified during ward rounds and by regular case 
record reviews during study period. The enrolled patients were followed from 
the day of admission till the day of discharge and the relevant study data 
including total direct costs which include direct medical costs, cost of laboratory 
investigations, cost of consultation, cost of hospitalization, direct nonmedical 
cost includes the transportation cost to hospital and indirect costs which include 
days lost from work or productivity, was documented in case record form. 
RESULTS: A total of 150 patients were enrolled during the study period. The 
average cost per diabetic patient without complications was Rs. 1623 this 
includes the average total direct medical cost was Rs.1483 (91.37%), the average 
direct non medical cost was Rs. 20 (1.23%) and the average total indirect cost was 
Rs. 120 (7.4%) compared to for those with diabetes complications, Rs. 7706 for 
macrovascular complications, Rs. 4907 for microvascular complications and Rs. 
2810 others infections. The cost for the treat diabetes with co morbidities was 
found to be Rs. 17046, the average total direct medical cost was Rs. 15738 
(92.41%), the average direct non medical cost was Rs. 204 (1.12%) and the average 
total indirect cost was Rs. 1104 (6.47%). CONCLUSIONS: Our study results 
